Salute e Benessere

2024 American Oncology Annual Meeting Concludes in Chicago, CANCER CASES SURGE…

Cancer Driver Interception: The New Frontier of Prevention Cancer Driver Interception: The New Frontier of Prevention Developed by a spin-off of the University of Rome Tor Vergata, the HELIXAFE protocol, using the Cancer Driver Inteception methodology, represents an active prevention strategy against conditions that can lead to cancer development. ProfessorAdriana Albini ,Head of the Cancer Prevention Working Group at AACR(American Association for Cancer Research), and Board...
PR Newswire
10/06/2024

ZINZINO AB (PUBL): ANNUAL REPORT ENGLISH 2023

For more information:Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com For more information:Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700,zinzino.com Pictures for publication free of charge: [email protected] Certified Adviser: Carnegie Investment Bank AB (publ) This information was brought to you by Cisionhttp://news.cision.com. https://news.cision.com/zinzino/r/zinzino-ab--publ--annual-report-english-2023,c3997891 The following...
PR Newswire
10/06/2024

PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with…

ResMed studies presented at SLEEP 2024 also revealed a 17% prevalence of insomnia among adults in North America, Latin America, and the Caribbean, and a higher rate of depression in women with OSA “The real-world evidence used in our clinical research continues to demonstrate the effectiveness of PAP therapy for treating OSA,” said Carlos M. Nunez, MD, ResMed's Chief Medical Officer. “The studies presented at SLEEP 2024 expand our understanding of patients with sleep disorders by examining...
Nasdaq GlobeNewswire
10/06/2024

Octapharma's continuing dedication to improving the lives of people with rare…

Bleeding disorders, such as haemophilia A and von Willebrand disease (VWD), carry the risk of recurrent and prolonged bleeds, which can not only be life-threatening but also take a heavy toll on patients' quality of life and mental health. Bleeding disorders, such as haemophilia A and von Willebrand disease (VWD), carry the risk of recurrent and prolonged bleeds, which can not only be life-threatening but also take a heavy toll on patients' quality of life and mental health. The...
PR Newswire
10/06/2024

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 10 June 2024– On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.Under the…
Nasdaq GlobeNewswire
10/06/2024

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA…

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody ®sonelokimab in Psoriatic Arthritis Builds upon the positive regulatory feedback received from FDA and EMA on Phase 3 VELA program for sonelokimab in hidradenitis suppurativa (HS), which has started recruitmentClarified path for PsA Phase 3 program with study design, patient population and endpoints agreed – program is called IZAR and two...
Nasdaq GlobeNewswire
10/06/2024

Eve Communications, Inc. to Showcase at What's Next Longevity Venture Summit…

"Loneliness and dementia are the twin epidemics of our time," says Ivan Wicksteed, Founder & CEO of Eve Communications. He refers to the Surgeon General's recent report, which equates loneliness to smoking 15 cigarettes per day. "Loneliness and dementia are the twin epidemics of our time," saysIvan Wicksteed, Founder & CEO of Eve Communications. He refers to the Surgeon General's recent report, which equates loneliness to smoking 15 cigarettes per day. Eve is…
PR Newswire
10/06/2024

Endo Launches New Dupuytren's Contracture Campaign: Reminders

"I've seen patients who've coped with Dupuytren's contracture for longer than necessary because a healthcare provider presented two paths: living with the condition or undergoing surgery," said Dr. Damon Adamany, an orthopedic hand surgeon at The CORE Institute. "I believe that if patients aren't comfortable with the options presented, they should get a second opinion." "I've seen patients who've coped with Dupuytren's contracture for longer than necessary because a…
PR Newswire
10/06/2024

Zymeworks Announces China NMPA Acceptance of Biologics License Application for…

Pursuant to the terms of the licensing agreement between Zymeworks and BeiGene, Zymeworks is entitled to receive an $8 million milestone payment from BeiGene and remains eligible to receive up to $164 million based on additional milestones plus royalties on product salesA Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer...
Nasdaq GlobeNewswire
10/06/2024

Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with…

Improvements in multiple sign efficacy endpoints were observed in full population and with predictive and more pronounced effects in the TNFR1 genetic biomarker population as identified in prior successful Phase 2 symptoms trialRapid treatment effect on corneal inflammation was observed in TNFR1 genetic biomarker patients as early as Day 15 and was statistically significant at final efficacy visit on Day 43Licaminlimab was well tolerated similar to vehicle Company plans to...
Nasdaq GlobeNewswire
10/06/2024

India Breakthrough: Bio Regenerative Precision Medicine Seminar Held in…

This comeback is primarily focused on education, research, and biopharmaceutical production, cooperating with the research institutions in India such as the Council of Scientific & Industrial Research- Centre for Cellular & Molecular Biology (CSIR-CCM)'s Atal Incubation Centre (AIC), the Centre for Cellular and Molecular Platforms (C-CAMP) in Bengaluru, International Institute of Information Technology (IIIT) Hyderabad, and others. This comeback is primarily focused on education…
PR Newswire
10/06/2024

Commit Biologics to present data on its Bispecific Complement Engaging (BiCE™)…

Poster Title: BiCE™ – An antibody platform to potentiate complement activation for the treatment of cancer and autoimmune diseasesPresenter: Dr Nick S. Laursen, Chief Scientific Officer and Co-Founder of Commit Biologics Poster Title:BiCE™ – An antibody platform to potentiate complement activation for the treatment of cancer and autoimmune diseasesPresenter:DrNick S. Laursen, Chief Scientific Officer and Co-Founder of Commit Biologics The data will reveal optimization of the...
PR Newswire
10/06/2024

Ariceum Therapeutics to Present Outstanding New Preclinical Data at the Society…

These data highlight the significantly higher tumor uptake and longer tumor retention leading to a higher tumor to background and tumor to kidney ratios of satoreotide which translates into higher pre-clinical efficacy than SST2-targeting agonists when labelled with isotopes, 225Ac-satoreotide and 177Lu-satoreotide. This demonstrates the potential for satoreotide to clinically outperform SST2-targeting agonists and strongly supports its further clinical development for the treatment of SST2…
PR Newswire
10/06/2024

XRP Healthcare Welcomes 10 Billion Dollar M&A Specialist Whitney Lynn to Head…

This strategic move comes as XRP Healthcare is set to embark on an ambitious mergers and acquisitions (M&A) venture, having successfully registered itstrademark inUganda . This crucial milestone paves the way for the consolidation, improvement, and integration of pharmacies, medical centres, and hospitals into a unified, high-performing conglomerate. Whitney Lynn'sappointment is also a crucial step in XRP Healthcare's journey towards operating as one cohesive entity,...
PR Newswire
10/06/2024

Nagase Viita Launches SOLBIOTE (TM), New Brand of Injectable-grade Saccharide…

Image1: SOLBIOTE (TM) portfolio; TREHALOSE SG and MALTOSE PH https://cdn.kyodonewsprwire.jp/prwfile/release/M104815/202406031668/_prw_PI1fl_MyQw9rBz.jpg Image1: SOLBIOTE (TM) portfolio; TREHALOSE SG and MALTOSE PHhttps://cdn.kyodonewsprwire.jp/prwfile/release/M104815/202406031668/_prw_PI1fl_MyQw9rBz.jpg Nagase Viita has a long history of harnessing the power of nature and an expertise in biotechnology, which led it to be the first to successfully mass produce trehalose utilizing starch...
PR Newswire
10/06/2024

J INTS BIO, ASCO 2024 - JIN-A02 showed tumor reductions including brain…

To-date, Partial Response (PR) has been confirmed in two patients and Stable Diseases in three other, including the patient with reduction of brain metastasis in Cohort 4 and two patients from the lower Cohorts at a lower dose. To-date, Partial Response (PR) has been confirmed in two patients and Stable Diseases in three other, including the patient with reduction of brain metastasis in Cohort 4 and two patients from the lower Cohorts at a lower dose. The final patient in Cohort 4 (100mg) is...
PR Newswire
10/06/2024

Rockit™ Apple fired up to Ready. Set. Rockit. into record season

Market Manager for the Middle East, Ziad El Chawa says 2024 is going to be a record year for Rockit in the Middle East, off the back of strong 31 percent growth in 2023 (versus 2022). Market Manager for theMiddle East,Ziad El Chawasays 2024 is going to be a record year for Rockit in theMiddle East, off the back of strong 31 percent growth in 2023 (versus 2022). "To drive consumer demand for increased volumes of Rockit™ apples arriving in market, we are focusing on interactive...
PR Newswire
10/06/2024

Distributor Orders Nexstim NBS System 5 for European Hospital

Press release, Helsinki, 10 June 2024 at 9 AM (EEST) Distributor Orders Nexstim NBS System 5 for European Hospital Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from a distributor for a European hospital.The Nexstim Navigated Brain Stimulation (NBS) System 5 is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus and localization of cortical areas that do not contain essential speech...
Nasdaq GlobeNewswire
10/06/2024

Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV…

The test uses highly sensitive PCR technology, requiring only a single nasal-swab sample to provide rapid, accurate qualitative detection and differentiation among four of the most prevalent respiratory viruses for which differential diagnosis can drive appropriate treatment.Enables healthcare professionals to make confident clinical decisions and promptly determine appropriate treatment, with definitive results reported in just 20 minutes.Expands Roche's extensive molecular point of...
Nasdaq GlobeNewswire
10/06/2024

European Commission approves Roche's Alecensa as the first and only targeted…

European Commission approves Roche's Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive resected non-small cell lung cancer, as demonstrated in the Phase III ALINA study 1 Alecensa's approval addresses an urgent unmet need in the early-stage setting where about half of all people experience disease recurrence...
Nasdaq GlobeNewswire
10/06/2024

Santhera Announces Launch of Early Access Program in China for AGAMREE® by its…

Pratteln, Switzerland, June 10, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that its partner Sperogenix Therapeutics has launched a paid-for Early Access Program (EAP) for AGAMREE® (vamorolone) in China for patients with Duchenne muscular dystrophy (DMD). In April 2024, the Hainan Medical Products Administration (HMPA) authorized the EAP for AGAMREE based on local policies, AGAMREE's existing overseas approvals (U.S., EU, UK) and its demonstrated ability to address urgent...
Nasdaq GlobeNewswire
10/06/2024

FDA accepts filing of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing…

Alzheimer's disease is a progressive disease caused by toxic amyloid proteins. Once established, this pathophysiological process continues through the patient's life and therefore sustained treatment is necessary. The treatment should be initiated as early as possible to maximize patient outcomes. Data from Studies 201, 301 and their OLEs show that continued treatment with LEQEMBI beyond the 18-month core phase prolongs the benefit as highly toxic protofibrils are continuously removed. If…
PR Newswire
10/06/2024

FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics…

TOKYO and CAMBRIDGE, Mass., June09, 2024(GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI ® ) intravenous (IV) maintenance dosing. A Prescription...
Nasdaq GlobeNewswire
10/06/2024

Calyx / Invicro Forges a Strategic Collaboration with BAMF Health to Accelerate…

A catalyzing project for this partnership is an actinium-225 initiative, for which TerraPower is supplying actinium-225, and BAMF is leveraging its GE HealthCare StarGuide™ SPECT/CT and dosimetry expertise to enhance the study and application of actinium-225 in RLT. A catalyzing project for this partnership is an actinium-225 initiative, for which TerraPower is supplying actinium-225, and BAMF is leveraging its GE HealthCareStarGuide ™ SPECT/CT and dosimetry expertise to enhance the study and...
PR Newswire
07/06/2024
Altri  Comunicati